Endothelial vasomotor function is impaired in a variety of disorders representing both early and late stages of atherosclerosis. There is experimental evidence for enhanced vascular angiotensinconverting enzyme (ACE) activity in these disorders. We explored whether enhanced vascular ACE activity accounts for endothelial dysfunction in experimental hypertension. Hypertension was induced in rats by coarctation of the aorta. At 2 weeks post-operation, the animals were randomly divided into groups receiving the ACE inhibitor quinapril (2.0 mg:kg − 1 :day − 1 ), the angiotensin type-1 receptor antagonist losartan (3.0 mg:kg − 1 :day − 1 ), the B 2 kinin receptor antagonist icatibant (0.4 mg:kg − 1 :day − 1 ), quinapril plus icatibant, losartan plus icatibant, or no drug. Analyses were performed 4 weeks post-operation. None of the drug treatments had any significant effect on blood pressure. ACE activity was nearly doubled in aortae from untreated hypertensive rats as compared with sham-operated rats. Quinapril reduced ACE activity in aortae from hypertensive rats by 75 %, losartan caused a 40 % decrease, and icatibant had no effect. Endothelium-dependent, nitric oxide-mediated vasodilator responses studied in vitro were impaired by 40 % in aortae from untreated hypertensive rats as compared with sham-operated rats. Both quinapril and losartan restored endothelial vasomotor function in aortae from hypertensive rats. Co-applied icatibant negated the effects of quinapril, but not those of losartan. The level of endothelial NO synthase (eNOS) mRNA determined by competitive RNA PCR was decreased by half in aortae from untreated hypertensive rats as compared with sham-operated rats. Quinapril induced an increase in the eNOS mRNA level of 350 % in aortae from hypertensive rats, which was negated by co-applied icatibant. Losartan restored eNOS mRNA expression in aortae from hypertensive rats to normal levels, and this effect was not modified by co-applied icatibant. These findings suggest that enhanced vascular ACE activity accounts for endothelial vasomotor dysfunction by impairing the bioavailability of endothelium-derived NO. Both enhanced formation of angiotensin II and enhanced metabolism of bradykinin might account for a vascular deficiency of bioactive NO. Abbreviations : ACE, angiotensin-converting enzyme ; AT " receptor, angiotensin type-1 receptor ; AAC rats, rats having undergone abdominal aortic coarctation ; TAC rats, rats having undergone thoracic aortic coarctation ; HHL, hippuryl-L-histidyl-L-leucine ; (e)NOS, (endothelial) nitric oxide synthase.
INTRODUCTION
The endothelium plays a fundamental and obligatory role in the control of vascular tone through the synthesis and release of vasoconstricting and vasodilating autacoids. Nitric oxide (NO), formed by the endothelial isoform of NO synthase (eNOS), is thought to be one of the most important autacoids derived from the endothelium [1] . NO not only induces potent smooth muscle relaxation, but also has a wide range of actions, promising a high anti-atherogenic potential. These include inhibition of platelet activation, platelet adhesion to the endothelium, platelet recruitment and release of mitogenic factors, all of which will reduce thrombotic processes [2] [3] [4] , downregulation of the endothelial expression of leucocyte adhesion molecules and of chemoattractants, which will attenuate infiltration of the vessel wall by leucocytes [5, 6] , inhibition of smooth muscle cell proliferation and migration [7, 8] and, finally, neutralization of reactive oxygen species and inhibition of their formation [9, 10] .
Angiotensin-converting enzyme (ACE), a zinc metallopeptidase which is predominantly localized at the endothelial cell membrane, plays an important role in the endothelial biosynthesis and metabolism of vasoactive autacoids [11] . It catalyses the cleavage of the C-terminal histidyl-leucine from angiotensin I to yield the potent vasoconstrictor angiotensin II. The same enzyme is also called kininase-II, and inactivates the potent vasodilator bradykinin by catalysing the cleavage of its C-terminal and penultimate dipeptides. Bradykinin acts through endothelial B # kinin receptors to stimulate the endothelial release of NO, prostacyclin and, in some vascular beds, a smooth-muscle-hyperpolarizing autacoid [12] . Angiotensin II induces vasoconstriction by stimulation of angiotensin type-1 (AT " ) receptors on smooth muscle cells [13] . It can also stimulate the endothelial release of vasoconstrictor autacoids (such as endothelin) or vasodilator autacoids (such as NO) through activation of endothelial angiotensin receptors [14, 15] . Angiotensin II not only is a potent vasoconstrictor, but can also induce a wide range of potentially pro-atherogenic actions ; these include the up-regulation of plasminogen activator inhibitor by endothelium and smooth muscle, hence reducing local fibrinolysis [16] , the up-regulation of smooth muscle expression of chemoattractants, provoking infiltration of the vessel wall by leucocytes [17] , the induction of smooth muscle proliferation [18, 19] and, finally, the activation of enzymes forming reactive oxygen species [20] .
The endothelium is functionally abnormal in such diverse disorders as hypertension and hypercholesterolaemia, which predispose subjects to atherosclerosis, myocardial infarction and heart failure (the latter two are clinical manifestations of atherosclerosis) [21] . A deficit in the bioavailability of NO appears to account for endothelial dysfunction in all of these disorders, although the molecular mechanisms underlying this deficit remain to be elucidated [22] . There is also experimental evidence for enhanced vascular ACE activity in hypertension, in hypercholesterolaemia and in vascular remodelling following angioplasty or chronic inhibition of NO synthesis [23] [24] [25] [26] . However, its role in the pathogenesis of these disorders and the molecular mechanisms determining it remain poorly understood.
Numerous experimental studies have shown that chronic ACE inhibitor treatment prevents or ameliorates endothelial dysfunction in hypertension and hypercholesterolaemia (e.g. [27] [28] [29] ). The first clinical evidence for improved endothelial vasomotor function as a result of chronic ACE inhibitor therapy was provided by the TREND (Trial on Reversing ENdothelial Dysfunction) study [30] . More recently, it was reported that chronic ACE inhibitor treatment significantly increased the endothelial release of NO in experimental hypertension [31] . However, no study to date has demonstrated that enhanced vascular ACE activity accounts for endothelial dysfunction or endothelial NO deficiency.
In the present study, we present evidence for a causal link between enhanced vascular ACE activity and impaired endothelial vasomotor function in experimental hypertension. We performed the study using rats with hypertension induced by aortic coarctation. We analysed ACE activity, vasomotion and eNOS expression in the descending thoracic aorta and studied hypertension-induced changes using two variants of aortic coarctation, one with this section of aorta proximal to the coarctation site, and the other with this section distal to it. We evaluated the effects of prolonged non-antihypertensive treatment with the ACE inhibitor quinapril or the AT " receptor antagonist losartan, or these drugs combined with the B # kinin receptor antagonist icatibant.
METHODS
The experiments were performed using male Wistar rats aged 9 weeks (SAVO) in accordance with our institutional guidelines on the care and use of laboratory animals and in compliance with the NIH guidelines (NIH publication no. 85-23).
Aortic coarctation
The animals were randomly divided into groups to undergo operation with coarctation of the abdominal aorta (AAC rats), operation with coarctation of the thoracic aorta (TAC rats), or sham operation. Anaesthesia was induced by intraperitoneal injection of ketamine (50 mg\kg, supplemented with xylazine, 5 mg\ kg). For coarctation of the abdominal aorta, a midline laparotomy was performed and a silk thread was passed under the aorta at a point just below the coeliacic trunk. A cannula with an outer diameter of 1.2 mm was placed longitudinally on the aorta, and both the aorta and cannula were tied. After removal of the cannula, the aorta was left constricted to the extent determined by the cannula's diameter. Sham-operated rats were subjected to the same surgical procedure, except for the ligature. For coarctation of the thoracic aorta, a lateral thoracotomy in the fourth left intercostal space was performed in anaesthetized, ventilated rats. The aorta was carefully dissected and ligated at a point just behind the aortic arch using a cannula with an outer diameter of 1.0 mm.
Drug treatments
AAC rats were randomly divided into groups to receive quinapril, 2.0 mg:kg −" :day −" (group AAC-Q, n l 11) ; losartan, 3.0 mg:kg −" :day −" (group AAC-L, n l 14) ; icatibant, 0.4 mg:kg −" :day −" (group AAC-I, n l 11) ; quinapril, 2.0 mg:kg −" :day −" , plus icatibant, 0.4 mg:kg −" :day −" (group AAC-QI, n l 11) ; losartan, 3.0 mg:kg −" :day −" , plus icatibant, 0.4 mg:kg −" :day −" (group AAC-LI, n l 10) ; or no drug (n l 14). Quinapril and losartan were administered via the drinking water, and icatibant was administered via an intraperitoneally implanted osmotic minipump (Alzet model 2002 ; Alza Corp.). Minipumps filled with solvent only were implanted in some rats of groups AAC-Q and AAC-L as placebo co-treatments. Quinapril and losartan at these doses were equally effective in blunting the pressure responses to intravenously applied angiotensin I and angiotensin II respectively. Treatment was started 2 weeks post-operation and continued for a further 2 weeks.
Determination of blood pressure
Blood pressure was determined 4 weeks after aortic coarctation, both proximal to the coarctation site and distal to it. Rats were anaesthetized with ketamine (50 mg\kg, intraperitoneally, supplemented with xylazine, 5 mg\kg). Polyethylene tubing (PE-50 and PE-10 ; Portex Ltd.) was inserted into the right carotid artery and the right femoral artery, and was connected to an Isotec pressure transducer (Sachs Ltd.). The pressure transducer was coupled to a custom-made differential amplifier, an oscilloscope (model HM 205-2 ; Hameg Ltd.) and a multi-channel recorder (model R-54 ; Rikadenki Ltd.). Carotid arterial and femoral arterial pressures were recorded continuously and simultaneously.
Determination of ACE activity
When the rat was killed, arterial blood was drawn into a syringe containing heparin. Cells and cell fragments were pelleted by centrifugation of the blood sample at 2500 g for 20 min. A 50 µl sample of the supernatant was added to 150 µl of phosphate buffer (100 mM NaH # PO % , 300 mM NaCl, pH 8.3) containing 4.95 mM hippuryl-Lhistidyl-L-leucine (HHL) and 0.05 mM ["%C]HHL (0.11 MBq\mmol), and the mixture was incubated for 30 min at 37 mC. The reaction was stopped by adding 1 ml of 1 M HCl, and the mixture was then extracted with 1 ml of water-saturated ethyl acetate. The ethyl acetate extract was separated by centrifugation at 2000 g for 20 min, then a 400 µl portion was mixed with 10 ml of scintillation cocktail, and radioactivity was determined by β-counting. Plasma ACE activity was expressed as nmol of HHL:min −" :ml −" .
For determination of aortic ACE activity, freshly harvested vessels were crushed in liquid nitrogen, incubated with 0.3 % Triton X-100 for 20 min on ice, and homogenized using an UltraTurrax. The homogenate was centrifuged at 13 000 g for 20 min, and a 50 µl portion of the supernatant was incubated at 37 mC for 60 min with HHL as described above. The protein content of the homogenate was measured by the method of Lowry et al. [32] , and aortic ACE activity was expressed as nmol of HHL:min −" :mg −" protein.
Vasomotor studies
Vasomotor studies were conducted as described previously [33] . The aorta was excised from an anaesthetized rat, and then cleaned and stripped of fat and connective tissue. Segments of the descending thoracic aorta (10-15 mm) were fixed between two cannulas in a custommade vessel bath [34] 38, in addition to extraluminal perfusion. The perfusion pressure was adjusted to 50 mmHg. Under these conditions, the mean outer aortic diameter determined by a photoelectric device [35] was 1695p54 µm for aortic segments of sham-operated and TAC rats (n l 20) and 2107p31 µm for aortic segments of untreated and drug-treated AAC rats (n l 63) (starting diameter). The drugs were applied intraluminally, and vasomotions were recorded continuously as changes of outer-vessel diameter. After precontraction with phenylephrine (1-5 µM) to 90 % of the starting diameter, vasodilation was studied in response to acetylcholine, histamine, calcium ionophore A23187 and sodium nitroprusside. A washout period for return to the initial precontraction level was allowed between each agonist. Vasodilator responses to sodium nitroprusside were determined during inhibition of endogenous NO for-mation by nitro-L-arginine (30 µM). At least three vessel segments in each group were exposed to the cyclooxygenase inhibitor indomethacin (30 µM) intra-and extra-luminally throughout the perfusion period. Vasodilation was expressed as a percentage of precontraction at a steady-state level.
Quantification of eNOS mRNA
eNOS mRNA was quantified by competitive RNA PCR, as described previously [33] . Briefly, total cellular RNA was isolated from 20-mm segments of the descending thoracic aorta by acid guanidinium thiocyanate\ phenol\chloroform extraction [36] . A fragment of bovine eNOS cDNA (positions 1017-1660 of the cDNA sequence ; GenBank accession no. M95674) with an internal deletion of 125 bp was cloned and subjected to in vitro transcription, and the eNOS-construct RNA was used as internal control and competitor in RNA PCR. Equal amounts of aortic total RNA (312.5 ng) together with different amounts of competitor eNOS RNA (500-6.25i10& molecules) were reverse-transcribed into firststrand cDNAs using random hexanucleotide primers and Moloney murine leukaemia virus reverse transcriptase. Target and competitor eNOS cDNAs were amplified by PCR using primer oligonucleotides designed on the basis of partially sequenced rat eNOS cDNA (R. Studer, unpublished work ; sense primer, 5h-CTGCGCTGGT-ATGCCCTCC-3h ; antisense primer, 5h-AAGAGCCT-CCCCAGCTGCTG-3h) and Taq DNA polymerase. The specificity of the amplified cDNAs was confirmed by sequence analysis and by hybridization with specific internal oligonucleotide probes. PCR was performed for 30 cycles at 94 mC for 1 min, 65 mC for 2 min and 72 mC for 3 min. The reaction products were separated by gel electrophoresis, stained with ethidium bromide, visualized by UV illumination and photographed. The amounts of target and competitor eNOS PCR products were determined by densitometric scanning of the film negative, and the original number of eNOS transcripts in the aortic sample was then calculated.
Reagents
Quinapril was supplied by Parke-Davis, losartan was supplied by Merck Sharp & Dohme, and icatibant was obtained from Hoechst. Moloney murine leukaemia virus reverse transcriptase was from Life Technologies. Taq DNA polymerase and ["%C]HHL were from Amersham. Phenylephrine hydrochloride, acetylcholine hydrochloride, histamine hydrochloride, calcium ionophore A23187, sodium nitroprusside, nitro-L-arginine and indomethacin were from Sigma. The stock solution of A23187 was prepared in DMSO and used at 1:20000 dilution. Sodium nitroprusside was dissolved in 1 mM sodium acetate and indomethacin was dissolved in ethanol\0.1 M NaHCO $ (1 : 3, v\v), and these stocks were used at 1 : 10 000 dilutions.
Statistical analysis
Data are presented as meanspS.E.M. Data were compared by two-way analysis of variance (aortic coarctationidrug treatment), and significance was established using Fisher's protected least-significant-difference test. A difference was considered statistically significant when P 0.05.
RESULTS

Blood pressure and body weight
The mean carotid arterial blood pressures of AAC and TAC rats studied 4 weeks after aortic coarctation were significantly greater than those of sham-operated rats (Table 1 ). In contrast, the mean femoral arterial pressures of AAC and TAC rats were similar to those of shamoperated animals. None of the drug treatments had any significant effect on either carotid arterial pressure or femoral arterial pressure of AAC rats. Body weights were not significantly different between coarctation hypertensive and sham-operated animals, and drug treatments had no significant effects on the body weight of AAC rats.
Plasma and aortic ACE activities
Plasma ACE activity determined 4 weeks post-operation was not significantly different between coarctation hypertensive and sham-operated rats (Table 1) . Treatment with quinapril reduced plasma ACE activity by about 70 %, whereas neither treatment with losartan nor treatment with icatibant had any effect on plasma ACE activity.
ACE activity was nearly doubled in the thoracic aortae from AAC rats when compared with sham-operated animals ( Figure 1 ). In contrast, the aortic ACE activity of TAC rats did not differ significantly from that of shamoperated rats. ACE activity in the thoracic aortae from quinapril-treated AAC rats was reduced by 75 % when compared with untreated AAC rats. Treatment of AAC rats with losartan led to a much less dramatic, but none the less significant, decrease in aortic ACE activity, to values similar to those of sham-operated rats. Icatibant had no effect on the aortic ACE activity of AAC rats, when administered either alone or in combination with quinapril or losartan.
Vasomotor function of the aorta
Dilator responses of precontracted aortic segments to acetylcholine were significantly attenuated in the thoracic aortae from AAC rats ; the maximal dilator response was Endothelial dysfunction in hypertension Drugs used were quinapril (-Q ; n l 10), losartan (-L ; n l 10) or icatibant (-I ; n l 11), or a combination of icatibant with quinapril (-QI ; n l 11) or losartan (-LI ; n l 9). Data represent meanspS.E.M. Significance of differences : *P 0.05 versus sham-operated ; †P 0.05 versus AAC rats.
reduced to 60 % of that of vessels from sham-operated animals ( Figure 2 ). In contrast, the acetylcholine-induced dilation of thoracic aortae taken from TAC rats was similar to that of aortae from sham-operated rats. Dilator responses to acetylcholine were nearly completely restored in thoracic aortae from AAC rats treated with quinapril ; the maximum dilator response was increased by 40 % when compared with untreated AAC rats. Similar effects were observed on treatment of AAC rats with losartan. Co-treatment with icatibant negated the effects of quinapril, but not those of losartan. Treatment of AAC rats with icatibant alone had no effect on acetylcholine-induced dilation of the thoracic aortae. Similar results were obtained with histamine, another endothelium-dependent and receptor-dependent vaso- Drugs used were quinapril (-Q ; n l 10), losartan (-L ; n l 9) or icatibant (-I ; n l 10), or a combination of icatibant with quinapril (-QI ; n l 11) or losartan (-LI ; n l 9). Data represent meanspS.E.M. Significance of differences : * P 0.05 versus sham-operated ; †P 0.05 versus AAC ; ‡P 0.05 versus AAC-Q. dilator, and with A23187, an endothelium-dependent but receptor-independent vasodilator (results not shown). Inhibition of prostanoid formation by indomethacin had no effect on the endothelium-dependent dilator responses of the thoracic aortae from any of the rats ; inhibition of endogenous NO formation by nitro-Larginine, however, negated the acetylcholine-, histamineand A23187-induced dilations of the thoracic aortae, implying that such dilation is mediated by endotheliumderived NO (results not shown). Vasodilator responses to the endothelium-independent agonist sodium nitroprusside were similar in all aortae studied (Figure 2) , although there was a tendency for a greater sensitivity to sodium nitroprusside in aortae from coarctation hypertensive rats when compared with sham-operated rats 
eNOS mRNA expression in the aorta
The number of eNOS transcripts in thoracic aortae from AAC rats was decreased by half when compared with sham-operated animals ( Figure 3 ). In contrast, the eNOS mRNA level in thoracic aortae from TAC rats did not differ significantly from values in sham-operated rats. The number of eNOS transcripts in thoracic aortae from quinapril-treated AAC rats was increased by 350 % when compared with untreated AAC rats. Treatment of AAC rats with losartan led to a much less dramatic, but none the less significant, increase in aortic eNOS transcript levels, to values similar to those in sham-operated animals. Co-treatment with icatibant negated the overexpression of eNOS mRNA induced by quinapril, whereas it had no effect on the up-regulation of eNOS mRNA expression induced by losartan. Treatment of AAC rats with icatibant alone did not induce any significant change in aortic eNOS mRNA expression.
DISCUSSION
The principal findings of this study are that endothelial dysfunction coincides with enhanced ACE activity in aortae of rats with coarctation hypertension and that, despite persistent hypertension, endothelial dysfunction is reversed after prolonged ACE inhibition. These findings suggest that enhanced vascular ACE activity accounts for impaired endothelial vasomotor function.
Because of the phenotypic diversity of endothelial and smooth muscle cells of different vascular beds, and even of different regions within the same vascular bed [37, 38] , we analysed ACE activity, vasomotion and eNOS expression in the same section of the rat aorta and studied hypertension-induced changes using two variants of aortic coarctation, one with the descending thoracic aorta proximal to the coarctation site, and the other with this section of the aorta distal to the coarctation site.
Thoracic aortae from AAC rats that had been exposed to elevated blood pressure displayed an impaired endothelial vasomotor function. In contrast, endotheliumdependent vasomotion was preserved in aortae from TAC rats that had been exposed to normal blood pressure. These findings are consistent with the results of clinical and experimental studies demonstrating endothelial dysfunction in hypertension [21] . Experimental evidence suggests that endothelium-derived vasoconstrictor prostanoids may account for hypertensionrelated endothelial dysfunction [39] . Since none of the dilator responses of aortae from any of the rats were affected by the cyclo-oxygenase inhibitor indomethacin, prostanoids are unlikely to have contributed to the endothelial dysfunction observed here. The endothelium-dependent dilator responses of the aortae were, however, completely abolished by the NOS inhibitor nitro-L-arginine, implying that they are mediated by endothelium-derived NO. The endothelial dysfunction observed in aortae that had been exposed to elevated blood pressure may thus reflect a deficiency in bioactive endothelium-derived NO. Previous studies have implied that a deficiency in downstream effectors of NO signalling may account for the apparent deficit in bioactive NO [40] . Since vasodilation in response to the NO donor sodium nitroprusside was preserved in aortae with endothelial dysfunction, impaired signalling downstream of NO is unlikely to underlie the NO deficit apparent here. However, endothelial dysfunction coincided with decreased expression of eNOS mRNA. This finding is in contrast with the results of previous studies, which have demonstrated that endothelial dysfunction is associated with increased eNOS expression in aortae from co-arctation hypertensive rats [41] . Subtle differences in the coarctation model and study design may explain these apparently incompatible observations. Our findings imply that the apparent deficit in bioactive endotheliumderived NO may be due, at least in part, to decreased expression of eNOS. Other potential mechanisms that reduce the bioavailability of NO, such as the enhanced vascular formation and release of superoxide [42] , have not been addressed here.
The mechanisms underlying the down-regulation of eNOS expression in aortae that had been exposed to elevated blood pressure remain a matter of speculation. Previous experimental evidence implies that the decreased expression of eNOS may be due to altered mechanical forces related to hypertension-induced vessel distension [43] .
The impaired endothelial vasomotor function observed in aortae that had been exposed to elevated blood pressure coincided with enhanced vascular ACE activity. Could enhanced ACE activity account for endothelial dysfunction ? Although it was shown previously that vascular ACE activity is enhanced in hypertension, whereas endothelial vasomotor function is impaired [21, 23] , these phenotypic changes have never been related with each other. This study provides the first evidence for a causal link between enhanced vascular ACE activity and impaired endothelial vasomotor function in experimental hypertension. We hypothesized that the endothelial vasomotor function of aortae that were exposed to elevated blood pressure in coarctation hypertensive rats would be restored by ACE inhibition if enhanced vascular ACE activity accounted for endothelial dysfunction. Indeed, aortae from coarctation hypertensive rats that had been treated with the ACE inhibitor quinapril displayed a nearly normal endothelial vasomotor function. Since the ACE inhibitor treatment had no effect on blood pressure, the restored endotheliumdependent vasomotion appears to be a specific result of ACE inhibition. In contrast, in most previous studies demonstrating improved endothelial vasomotor function following ACE inhibition in experimental hypertension, anti-hypertensive ACE inhibitor doses were used, and hence non-specific effects due to reduced blood pressure were included in those observations [27, [44] [45] [46] .
The ACE-inhibitor-induced recovery of endothelial vasomotor function in experimental hypertension has been attributed to the enhanced release of NO, the reduced release of vasoconstrictor prostanoids or the enhanced release of a smooth-muscle-hyperpolarizing autacoid from the endothelium [44] [45] [46] . Since the endothelium-dependent dilator responses of aortae from ACE-inhibitor-treated hypertensive rats were not modified by inhibition of cyclo-oxygenase, but were completely abolished by inhibition of NOS, the recovery of endothelial vasomotor function observed here appears to be the result of an enhanced release of NO. Since the dilator responses to exogenous NO were similar in aortae from treated and untreated hypertensive rats, altered signalling downstream of NO as a result of prolonged ACE inhibition is unlikely to account for the restored bioactivity of NO. However, the recovery of endothelial vasomotor function coincided with overexpression of eNOS mRNA. This finding is consistent with the results of previous studies, which have shown that the increase in endothelial NO formation resulting from chronic ACE inhibition is associated with increased expression of eNOS and decreased formation of superoxide in aortae from spontaneously hypertensive rats [31] . Our results imply that the restored bioavailability of NO after prolonged ACE inhibition may be due primarily to enhanced endothelial biosynthesis of NO. Other mechanisms that may account for the apparent increase in the endothelial release of NO, such as the decreased vascular formation and release of superoxide, have not been explored here.
The ACE-inhibitor-induced recovery of endothelial vasomotor function and overexpression of eNOS mRNA in aortae from coarctation hypertensive rats were negated by simultaneous B # kinin receptor antagonism, suggesting that these effects are kinin-mediated. This is the first demonstration of a role for endogenous kinins in enhancing the endothelial formation and release of NO during ACE inhibition in experimental hypertension.
Based on the present findings, it is tempting to conclude that vascular kinin deficiency as a result of persistently enhanced vascular ACE activity may account for the impaired endothelial formation and release of NO. However, caution may be warranted in drawing such conclusions. First, previous studies have shown that acute ACE inhibition in vitro as well as prolonged ACE inhibition in vivo leads to an accumulation of kinins at local tissue sites, which appears to be necessary for influencing vasomotor tone [47] [48] [49] . Secondly, there is experimental evidence suggesting that the effects of ACE inhibitors on endothelial vasomotor function are not merely the result of the local accumulation of kinins, but may also involve an interaction of ACE inhibitors with the B # kinin receptor itself, or with downstream signalling proteins [50] . Thirdly, there is also evidence for enhanced formation of angiotensin metabolites, due to a redirected metabolism of angiotensin I by ACE inhibition, which stimulate the endothelial release of vasodilator autacoids such as NO [47, 51, 52] . Therefore the contribution of a kinin deficiency to endothelial dysfunction may be overestimated. Instead, accumulation of angiotensin II as a result of persistently enhanced vascular ACE activity may also account for endothelial dysfunction.
We explored the potential role of angiotensin II by comparing the effects of prolonged ACE inhibition with those of equivalent AT " receptor antagonism. As observed for ACE inhibition, aortae from coarctation hypertensive rats that had been treated with the AT " receptor antagonist losartan displayed a near-normal endothelial vasomotor function. Since the treatment with losartan had no effect on blood pressure, the restored endothelium-dependent vasomotion appears to be a specific result of AT " receptor blockade. These findings are consistent with the results of previous studies, although, in those studies, anti-hypertensive doses of AT " receptor antagonists were used and hence nonspecific effects due to reduced blood pressure were included in those findings [53] .
As observed for ACE inhibition, the endotheliumdependent dilator responses of aortae from losartantreated hypertensive rats were not modified by inhibition of cyclo-oxygenase, but were completely abolished by inhibition of NOS. Thus the recovery of endothelial vasomotor function due to AT " receptor blockade appears to be the result of an enhanced release of NO. These findings are consistent with the results of previous studies demonstrating enhanced formation and release of NO during AT " receptor blockade, which appears to be due to enhanced stimulation of an as yet unidentified AT receptor by accumulating angiotensin II or its metabolites [54, 55] .
As observed for ACE inhibition, the dilator responses to exogenous NO were similar in aortae from treated and untreated hypertensive rats, suggesting that altered signalling downstream of NO as a result of prolonged AT " receptor blockade is unlikely to account for the restored bioactivity of NO. However, the recovery of endothelial vasomotor function coincided with restored expression of eNOS mRNA. This finding implies that the restored bioavailability of NO after prolonged AT " receptor blockade may be due to enhanced endothelial biosynthesis of NO, although other potential effects of AT " receptor blockade, such as the decreased formation of superoxide [56] or the decreased formation of endothelin [57] , may also be involved.
Unexpectedly, vascular ACE activity and ACE mRNA expression (results not shown) were reduced to nearnormal values in aortae from losartan-treated hypertensive rats. These effects may reflect an AT " -receptormediated positive-feedback regulation of ACE by angiotensin at local tissue sites under these pathophysiological conditions. These effects also imply that a relatively enhanced local bioavailability of kinins may contribute to the losartan-induced recovery of endothelial vasomotor function. However, the effects of AT " receptor blockade were not altered by simultaneous B # kinin receptor antagonism, excluding a contribution of endogenous kinins.
In summary, the results of the present study suggest that enhanced vascular ACE activity accounts for endothelial dysfunction by impairing the bioavailability of endothelium-derived NO. Both kinin deficiency and the accumulation of angiotensin within the vessel wall as a result of persistently enhanced local ACE activity might account for a vascular deficiency of bioactive NO. Given the anti-atherogenic potential of NO and the proatherogenic potential of angiotensin, such a causal link also implies a critical role for enhanced local ACE activity in the pathogenesis of atherosclerosis.
